Comtan (entacapone) / Novartis, Orion Corp, Alvogen - LARVOL DELTA

Outcome of People with Parkinson's Disease Treated with Levodopa-Entacapone-Carbidopa Intestinal Gel Who Failed Previous Subcutaneous Foslevodopa/Foscarbidopa. (PubMed, Brain Sci) - "From Vpre to Vpost, "Off" time was reduced in 2.9 ± 1.9 h (p = 0.002) and motor symptoms burden improved significantly (p = 0.013), whereas a trend of significance was found for non-motor symptoms burden (p = 0.050) and quality of life (p = 0.126). LECIG could be an alternative therapeutic option in PwP who failed fLD/fCD."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Movement Disorders • Parkinson's Disease

EFFECTS OF MAO-B AND COMT INHIBITORS ON SLEEP DISTURBANCES IN PARKINSON'S DISEASE: A NETWORK META-ANALYSIS (ADPD 2026) - "Inclusion criteria involved (1) patients with PD, (2) intervention/comparator consisting of MAO-B inhibitors (safinamide, rasagiline, or selegiline) and COMT inhibitors (opicapone, entacapone, or tolcapone), and (3) outcomes of improvement in parameters for subjective and objective sleep in randomized controlled trials and cohort studies. A total of 529 articles were identified during the initial search, and we ultimately conducted an NMA focusing on the final seven studies. Evidence has shown that safinamide is effective in improving objective sleep parameters in patients with PD. However, given the paucity of evidence and controlled, long-term studies, the effects of MAO-B and COMT inhibitors on sleep disturbances remain unclear. More high-quality studies will be needed and should enable clinicians to provide personalized medicine based on sleep profiles."

Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • Sleep Disorder • COMT

EFFICACY OF MAO-B AND COMT INHIBITORS ON QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE: A BAYESIAN NETWORK META-ANALYSIS (ADPD 2026) - "Randomized controlled trials evaluating QoL using PDQ-39 or PDQ-8 in patients treated with MAO-B inhibitors (rasagiline, selegiline, safinamide) or COMT inhibitors (entacapone, opicapone, tolcapone) were included. This network meta-analysis provides evidence that MAO-B inhibitors, particularly rasagiline and safinamide, may offer broader QoL benefits in patients with PD, especially in NMS such as emotional well-being. These findings support a more symptom-oriented and individualized treatment approach should be provided to patients with PD. Further well-designed head-to-head studies using standardized QoL measures and extended follow-up are needed to confirm these findings and guide clinical practice."

HEOR • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

[18F]F-DOPA Imaging in Patients With Autonomic Failure (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Daniel Claassen | Trial completion date: Feb 2026 ➔ Feb 2027 | Trial primary completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia • Lewy Body Disease • Movement Disorders • Multiple System Atrophy • Parkinson's Disease

Case Report: A possible novel adult-onset, progressive MAO-A hypofunction. (PubMed, Front Neurosci) - "The nature of the pathophysiology was then tested first by fractionated plasma catecholamine assays, performed at baseline and again using entacapone challenge to suppress catechol-O-methyltransferase function. Treatment consistent with the hypothesis consisted of rasagiline or selegiline combined with carvedilol. This treatment relieved all symptoms."

Journal • COMT

Comparative Efficacy of Opicapone and Entacapone in the Management of Motor Fluctuations in Parkinson's Disease (AAN 2026) - "Compared to ENT, OPC provides numerically higher reduction of "Off" time, increased "On" time, and a higher proportion of patients reporting meaningful clinical improvement. The benefit was maintained in the OLE study, further supporting its long-term efficacy."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Delayed-onset Parkinsonism Following BCMA-directed CAR-T Therapy (AAN 2026) - "He received high-dose dexamethasone with a prednisone taper. He showed poor response to sequential monotherapies, including carbidopa/levodopa, carbidopa/levodopa plus entacapone, ropinirole and rotigotine. Combination therapy with rotigotine, amantadine, and levodopa induced hallucinations. Midodrine improved orthostasis, but overall pharmacological response was minimal... This case underscores MNT as a significant delayed complication of BCMA-directed CAR-T therapy, aligning with European Society for Blood and Marrow Transplantation (EBMT) guidelines. It emphasizes the need for extended neurological surveillance, recognition of limited dopaminergic therapy efficacy, early immunomodulatory interventions despite inconsistent results and involvement in registries to better elucidate prevalence, underlying mechanisms, and optimal management strategies."

IO biomarker • CNS Disorders • Depression • Gastrointestinal Disorder • Hematological Malignancies • Hypotension • Infectious Disease • Inflammation • Movement Disorders • Multiple Myeloma • Parkinson's Disease • Septic Shock

According to a report by Zhitong Finance, Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced that the company recently received the 'Drug Registration Certificate' for Entacapone Tablets (hereinafter referred to as 'this product') issued by the National Medical Products Administration. (FUTU)

China filing • Parkinson's Disease

Consensus Molecules Associated with Parkinson's Disease. (PubMed, Neurol Int) - "Drugs include L-dopa (49%), carbidopa (63%), benserazide (50%), entacapone (74%), tolcapone (56%), rasagiline (76%), selegiline (46%), pargyline (4%), ropinirole (61%), pramipexole (56%), lisuride (27%), cabergoline (16%), bromocriptine (12%), and zonisamide (9%). Adjunctive therapies include droxidopa (33%), trihexyphenidyl (28%), biperiden (17%), amantadine (24%), memantine (7%), rivastigmine (13%), donepezil (6%), galantamine (4%), domperidone (6%), clonazepam (4%), tetrabenazine (16%), mazindol (13%), quetiapine (6%), and clozapine (4%). Contraindicated drugs include haloperidol (4%), sulpiride (3%), and methyldopa (6%)...Chemical inducers of PD include 6-hydroxydopamine (40%), N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 78%), tetrahydropyridine (77%), probenecid (4%), quinolinic acid (4%), 1,2,3,4-tetrahydroisoquinoline (TIQ, 16%), salsolinol (32%), rotenone (25%), and β-Methylamino-L-alanine (BMAA, 29%). Notably, our study highlights conditional essential..."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson's disease: a Bayesian network meta-analysis. (PubMed, Front Neurol) - "Randomized controlled trials evaluating QoL using PDQ-39 or PDQ-8 in patients treated with MAO-B inhibitors (rasagiline, selegiline, safinamide) or COMT inhibitors (entacapone, opicapone, tolcapone) were included. Further well-designed head-to-head studies using standardized QoL measures and extended follow-up are needed to confirm these findings and guide clinical practice. Registered in PROSPERO (CRD420251013028): https://www.crd.york.ac.uk/PROSPERO/view/CRD420251013028."

HEOR • Journal • Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Pharmacokinetics and pharmacodynamics of anti-Parkinson drugs in geriatric patients : Key for optimization of treatment (PubMed, Z Gerontol Geriatr) - "The decarboxylase inhibitors benserazide and carbidopa possess different t1/2...Absorption and elimination of entacapone and opicapone are similar to levodopa...Rasagiline and selegiline are irreversible inhibitors of monoamine oxidase B. Therefore, in spite of their short t1/2 they are dosed once daily...Clinically established dopamine agonists activate D1/D5 dopamine motor receptors less strongly than the dopaminergic receptors of D2/D3/D4group. This is a probable reason for their numerous adverse effects particularly in older people with Parkinson's disease."

Journal • PK/PD data • CNS Disorders • Geriatric Disorders • Movement Disorders • Parkinson's Disease • COMT

Biogenic Silver Nanoparticles via Microwave-Assisted Green Synthesis: Antimicrobial Agents and Fluorescent Nanosensors for the Sensitive Determination of Entacapone and Thiopental in Human Plasma and Dosage Forms. (PubMed, Luminescence) - "This dual functionality highlights their potential as a multifunctional theranostic detect-and-treat nanoplatform integrating diagnostic sensing with antimicrobial action. The greenness of the method was assessed using AGSA and ComplexMoGAPI tools, and the method was validated according to ICH Q2(R2) guidelines."

Journal

Exploratory Clinical Study ofEntacapone Combined with PD-1/L1 Antibody andTargeted Therapy in Advanced Hepatocellular Carcinoma Refractory to StandardTreatment (ChiCTR) - P=N/A | N=32 | Recruiting | Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

Demographics, treatment patterns, and healthcare resource utilization in Parkinson's disease: a real-world data study using a claims database. (PubMed, Arq Neuropsiquiatr) - "The most used medications were pramipexole (45.6%), amantadine (26.0%), and entacapone (17.1%).The present study provides valuable insights into the demographic and clinical profile of PD patients in Brazil, highlighting frequent procedures and treatment patterns. A key limitation is the non-capture of basic PD medications, such as levodopa, which are often dispensed outside the analyzed datasets. These findings underscore the need for improved data integration and access to comprehensive PD care within the public health system."

HEOR • Journal • Observational data • Real-world evidence • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

CauReL: Dynamic Counterfactual Learning for Precision Drug Repurposing in Alzheimer's Disease. (PubMed, Res Sq) - "Twenty drugs showed consistent protective associations, with four emerging as highly reproducible across both networks, the metabolic agents liraglutide and empagliflozin and the neuroactive agents entacapone and amantadine. Metabolic drugs produced the strongest benefits in individuals with diabetes, obesity, or cardiovascular disease, whereas neuroactive drugs provided broadly consistent protection across most subgroups.CauReL is available as an open source Python package with a companion web server for direct application to new cohorts or disease settings (https://caurel.site/). This work delivers a scalable and interpretable framework for prioritizing repurposable drugs and designing targeted clinical trials for the patients most likely to benefit."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Taxonomic and mechanistic insights into gut microbiota bioaccumulation of entacapone using bioorthogonal drug labelling. (PubMed, Microbiome Res Rep) - " Our findings reveal that entacapone is widely bioaccumulated by the gut microbiota across three donors and identify a key molecular mediator of this accumulation. This study expands the toolkit for investigating drug-microbiome interactions and holds significant potential to advance our understanding of drug-microbiome dynamics and therapeutic outcomes."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Epigenetic regulation of NAFLD: A preclinical study. (PubMed, Indian J Med Res) - "Pharmacological inhibition of mFTO by entacapone restored m6A marks on gene transcripts and reversed the NAFLD phenotype. Interpretation & conclusions Gene expression profiling identified key metabolic pathways and molecular targets associated with NAFLD progression. It underscored the role of mFTO in altering the m6A methylation landscape essential for establishing NAFLD and highlighted its therapeutic potential for NAFLD-associated morbidities."

Journal • Preclinical • Fibrosis • Genetic Disorders • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Effects of Combined Entacapone and rTMS Therapy on Pain Severity and Serum Inflammatory Biomarkers (IL-6 and TNF-α) in Parkinson's Disease. (PubMed, Brain Res Bull) - "High-frequency rTMS, as a non-invasive neuromodulation technique combined with EN, improves muscle rigidity, alleviates depressive symptoms, reduces pain, and attenuates inflammatory factor secretion in PD patients, can improve muscle tension, regulate depression, relieve pain, and reduce the secretion of inflammatory factors in Parkinson's patients.This combined therapy was clinically effective and demonstrated a favorable safety profile, with no serious adverse events reported and only mild, transient side effects (e.g., scalp discomfort, headache) observed in the rTMS group. However, its long-term efficacy requires further investigation."

Biomarker • Journal • CNS Disorders • Depression • Movement Disorders • Oncology • Pain • Parkinson's Disease • Psychiatry • IL6 • TNFA

Voltammetric analysis of entacapone, levodopa, and carbidopa in tablets: A chemometric approach. (PubMed, J Pharm Biomed Anal) - "The objective of the present work is to develop a voltammetric method for the determination of entacapone (ENT) in the presence of levodopa (LEV) and carbidopa (CAR) in synthetic mixtures and pharmaceutical formulations, using a multivariate approach. To evaluate the validity of the recommended method, a commercial pharmaceutical tablet (Stalevo ® 200 mg) was analyzed. RBF model has the ability to overcome difficulties such as non-linearity and overlaps in the voltammograms."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

A Randomized, Open-Label, Single-Dose, Two-Sequence, Four-Period, Replicate Crossover Bioequivalence Study of Entacapone Tablets in Fasting and Fed States Among Healthy Chinese Participants. (ChiCTR) - P=N/A | N=60 | Not yet recruiting | Sponsor: The First Hospital of Hebei Medical University; The First Hospital of Hebei Medical University

New trial • CNS Disorders • Movement Disorders • Parkinson's Disease

The possible protective effect of entacapone on hepatic fibrosis via the fat mass and obesity-associated protein/ N6-methyladenosine/ silent information regulator 1 pathway in a rat model. (PubMed, J Pharmacol Exp Ther) - "The current study may offer entacapone as a promising approach for liver protection during fibrosis. SIGNIFICANCE STATEMENT: The current study suggests that entacapone could increase silent information regulator 1 expression through its effect on fat mass and obesity-associated protein and N6-methyladenosine modulation, providing a promising approach for protecting the liver during fibrosis and identifying a potential new molecular target for the prevention of liver fibrosis."

Journal • Preclinical • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Obesity • FTO

Infusion therapies for Parkinson's disease: where are we in 2025? (PubMed, Expert Opin Drug Deliv) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Treatment Of Advanced Parkinson's With Levodopa–Entacapone–Carbidopa Intestinal Gel – Impact On Dyskinesia (MDS Congress 2025) - P | "Data from ELEGANCE suggest that long-term treatment with LECIG can improve the daily duration of dyskinesia. In the small number of patients who switched from LCIG to LECIG, there was a trend for a slight reduction in daily hours of dyskinesia. Figure 1 Figure 2"

Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Sustained Motor Symptom Efficacy With Long-Term Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Treatment – Data From The ELEGANCE Interim Analysis (MDS Congress 2025) - P | "LECIG showed sustained clinical efficacy in reducing PD motor symptoms, both during the day and at night, following treatment for up to two years. Figure 1 Figure 2 Figure 3"

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis (MDS Congress 2025) - P | "These data suggest that LECIG treatment for up to one year is generally well tolerated by patients with advanced PD. As has been observed with levodopa–carbidopa intestinal gel infusion, the most frequent AEs are associated with the procedure or the device. Table 1"

Adverse events • CNS Disorders • Movement Disorders • Parkinson's Disease